Nextbiomedical Co. Ltd.

As of June 30, 2026, Nextbiomedical Co. Ltd. carries a market capitalization of 339.64B, placing it among publicly traded companies globally. Its enterprise value stands at 311.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nextbiomedical Co. Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Nextbiomedical Co. Ltd. has 8.20M shares outstanding.

As of June 30, 2026, Nextbiomedical Co. Ltd. trades at a trailing price-to-earnings ratio of 1,457.81. The price-to-sales ratio is 19.06, and the price-to-book ratio stands at 6.91.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Nextbiomedical Co. Ltd. trades at an EV/FCF ratio of 3,446.98, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 311.60B versus a market cap of 339.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nextbiomedical Co. Ltd. maintains a current ratio of 5.02, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.14, indicating elevated leverage, while an interest coverage ratio of -6.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nextbiomedical Co. Ltd. posted a return on equity (ROE) of 0.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -4.08, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.38, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.89, useful for judging operating efficiency across full business cycles. The company generates approximately 225.89M in revenue per employee across its workforce of 78.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.87 indicates how many times Nextbiomedical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Nextbiomedical Co. Ltd.'s stock has declined approximately 56.34% over the past 52 weeks. The 50-day moving average sits at 31,302.00, while the 200-day moving average is 52,772.25.

Over the twelve months ended June 30, 2026, Nextbiomedical Co. Ltd. generated 17.79B in revenue and converted that into 232.56M in net income, yielding earnings per share of 28.40. EBITDA reached -1.76B, while operating income came in at -2.30B.

As of June 30, 2026, Nextbiomedical Co. Ltd. holds 34.99B in cash and equivalents against 6.95B in total debt, resulting in a net debt position of -7.13B. Total book value stands at 49.16B, with working capital of 35.42B providing operational flexibility.

Nextbiomedical Co. Ltd. produced 842.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.02B in capital expenditures, free cash flow totaled -180.14M - equivalent to -22.00 per share.

Over the twelve months ended June 30, 2026, Nextbiomedical Co. Ltd. posted a gross margin of 70.49, reflecting its pricing power and cost economics. The operating margin of -12.92 and net profit margin of 1.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nextbiomedical Co. Ltd. shareholders.

As of June 30, 2026, Nextbiomedical Co. Ltd. has an Altman Z-Score of 13.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.